Navigation Links
New Treatment Offers Hope for Beating Aggressive Cancers
Date:4/28/2008

NASHVILLE, Tenn., April 29 /PRNewswire/ -- With an 89% initial success rate in arresting or eradicating some of the most aggressive cancers, a Nashville-based treatment is being offered to the public for the first time. According to NeoPlas Innovation Director of Research Dr. Stephen Cantrell, gathering more data to validate effectiveness is imperative, but "early human results are quite exciting. This treatment has been effective for malignant melanoma, as well as pancreatic and some of the other worst-prognosis cancers."

The new protocol incorporates a unique combination of FDA-approved drugs already known to be safe, each used by millions of people for other applications. When administered alone, these drugs show some benefit against cancer, but not enough to make a difference for most patients. The combination of the medicines, however, allows lower, more tolerable dosages and provides effectiveness not seen in previous single-drug studies.

The NeoPlas treatment shows benefit in several aggressive malignancies because it disables certain abnormal cellular processes many of them share. Based on experience and relevant lab research to date, staff members expect the best results for melanoma, pancreatic cancer, colon cancer, renal (kidney) cancer, mesothelioma, and a group of sarcomas, including osteosarcoma, chondrosarcoma and malignant fibrous histiocytoma. Patients who have other cancers can be considered on a case-by-case basis, since many of them may benefit also. Having received previous cancer treatments does not make a patient ineligible.

The regimen's most notable side-effect is fatigue. Most patients never experience nausea, vomiting, hair loss, bone marrow or immune system suppression, or other side-effects commonly affiliated with chemotherapy or radiation. An experienced physician prescribes and monitors all treatment and maintains close communication with the patient's established oncologist.

NeoPlas Innovation serves patients living throughout the country. Since treatment takes place on an outpatient basis, most patients travel to Nashville about once every two months. Additionally, physicians usually can tell if the program is working within eight weeks and quickly enable patients to make their best healthcare decisions.

NeoPlas Innovation's web site, http://www.neoplas.org , provides complete information and an interactive screening tool for patients who are considering this treatment. The center can be reached by calling 615-371-8100 or e-mailing office@neoplas.org.


'/>"/>
SOURCE NeoPlas Innovation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Dental Convention to Highlight Latest Breakthroughs in Oral Health Treatments
2. Study shows false memories complicate end-of-life treatment decisions
3. HHS, Cleveland Clinic Collaborate to Advance Treatment for Neurological Disorders
4. Autistic mannerisms reduced by sensory treatment
5. Mutation database helps personalized treatment of lung cancer
6. UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers
7. ACTwatch, to Improve Malaria Treatment, to Be Launched on World Malaria Day
8. Study finds racial disparities in smoking cessation treatment
9. Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability
10. Annual Trachoma Treatments May Be Unnecessary
11. Discovery to hasten new malaria treatments, vaccines for children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... ... for the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 ... , Dr. Maisel, founder of Retina Group of New York , is ...
(Date:5/26/2016)... , ... May 26, 2016 , ... In an effort to provide hair restoration information ... both Snapchat users and those who do not use the app. Dr. Mohebi, the founder ... page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response to ...
(Date:5/26/2016)... ... 26, 2016 , ... Leadership of Life Science Logistics (LSL), ... has earned its ISO 13485 certification, indicating the company’s quality control system for ... policies associated with ISO quality standard 13485. , BSI Group America, Inc., ...
(Date:5/26/2016)... ... 2016 , ... The Lung Institute has partnered with the Gulfcoast ... June 6 at their clinic in downtown Tampa. The class is complimentary for the ... has created a free downloadable 4 Week Smoking Cessation Guide for those ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... offering campers a multitude of activities from daily practices, arts & crafts, discussions, ... Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds in kids’ yoga, ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016   ... beide primären Endpunkte und demonstriert Ebenbürtigkeit ... ‚ausgezeichneter plus guter , ... ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... neue positive Daten von der MORA-Studie der Phase ...
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
(Date:5/24/2016)... , May 24, 2016 ... Education in Clinical Neurophysiology  Elsevier , ... products and services, today announced the launch of ... open access journal that focuses on clinical practice issues ... case reports, clinical series, normal values and didactic reviews. ...
Breaking Medicine Technology: